Clinical experience with oxendolone for treatment of benign prostatic hyperplasia. Clinical efficacy and effects on serum lipid and lipoprotein fraction levels

Clinical experience with oxendolone for treatment of benign prostatic hyperplasia. Clinical efficacy and effects on serum lipid and lipoprotein fraction levels

Forty-three patients with benign prostatic hyperplasia were treated with weekly i.m. injections of 400 mg oxendolone for 12 weeks. The subjective symptoms were improved in 83% of these patients. Residual urine was decreased significantly and Qmax was increased by this treatment. Serum VLDL level was...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Hinyokika kiyo. Acta urologica Japonica. - 1962. - 30(1984), 4 vom: 01. Apr., Seite 537-43
1. Verfasser: Yasukawa, A (VerfasserIn)
Weitere Verfasser: Nihira, H, Matsuki, S, Fujii, M, Fujiwara, H, Kitano, T, Kodama, M, Ukai, R, Tado, O, Sagami, K
Format: Aufsatz
Sprache:Japanese
Veröffentlicht: 1984
Zugriff auf das übergeordnete Werk:Hinyokika kiyo. Acta urologica Japonica
Schlagworte:English Abstract Journal Article Androgen Antagonists Lipids Lipoproteins Nandrolone 6PG9VR430D oxendolone MN4I850D4P
LEADER 01000caa a22002652 4500
001 NLM061848425
003 DE-627
005 20250128074014.0
007 tu
008 231221s1984 xx ||||| 00| ||jpn c
028 5 2 |a pubmed25n0206.xml 
035 |a (DE-627)NLM061848425 
035 |a (NLM)6207714 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a jpn 
100 1 |a Yasukawa, A  |e verfasserin  |4 aut 
245 1 0 |a Clinical experience with oxendolone for treatment of benign prostatic hyperplasia. Clinical efficacy and effects on serum lipid and lipoprotein fraction levels 
264 1 |c 1984 
336 |a Text  |b txt  |2 rdacontent 
337 |a ohne Hilfsmittel zu benutzen  |b n  |2 rdamedia 
338 |a Band  |b nc  |2 rdacarrier 
500 |a Date Completed 02.11.1984 
500 |a Date Revised 19.11.2015 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a Forty-three patients with benign prostatic hyperplasia were treated with weekly i.m. injections of 400 mg oxendolone for 12 weeks. The subjective symptoms were improved in 83% of these patients. Residual urine was decreased significantly and Qmax was increased by this treatment. Serum VLDL level was suppressed significantly, whereas the levels of LDL, total cholesterol, HDL-cholesterol and triglycerides were changed little. Atherosclerotic index and the ratio of (total cholesterol--HDL-cholesterol) to (HDL-cholesterol), was not influenced by the treatment. No severe side-effect was found. These findings suggest that oxendolone is the drug of choice for non-surgical treatment of benign prostatic hyperplasia 
650 4 |a English Abstract 
650 4 |a Journal Article 
650 7 |a Androgen Antagonists  |2 NLM 
650 7 |a Lipids  |2 NLM 
650 7 |a Lipoproteins  |2 NLM 
650 7 |a Nandrolone  |2 NLM 
650 7 |a 6PG9VR430D  |2 NLM 
650 7 |a oxendolone  |2 NLM 
650 7 |a MN4I850D4P  |2 NLM 
700 1 |a Nihira, H  |e verfasserin  |4 aut 
700 1 |a Matsuki, S  |e verfasserin  |4 aut 
700 1 |a Fujii, M  |e verfasserin  |4 aut 
700 1 |a Fujiwara, H  |e verfasserin  |4 aut 
700 1 |a Kitano, T  |e verfasserin  |4 aut 
700 1 |a Kodama, M  |e verfasserin  |4 aut 
700 1 |a Ukai, R  |e verfasserin  |4 aut 
700 1 |a Tado, O  |e verfasserin  |4 aut 
700 1 |a Sagami, K  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Hinyokika kiyo. Acta urologica Japonica  |d 1962  |g 30(1984), 4 vom: 01. Apr., Seite 537-43  |w (DE-627)NLM012631779  |x 0018-1994  |7 nnns 
773 1 8 |g volume:30  |g year:1984  |g number:4  |g day:01  |g month:04  |g pages:537-43 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_20 
912 |a GBV_ILN_22 
912 |a GBV_ILN_40 
912 |a GBV_ILN_60 
912 |a GBV_ILN_72 
912 |a GBV_ILN_120 
912 |a GBV_ILN_350 
912 |a GBV_ILN_2001 
912 |a GBV_ILN_2003 
912 |a GBV_ILN_2005 
912 |a GBV_ILN_2006 
912 |a GBV_ILN_2008 
912 |a GBV_ILN_2010 
912 |a GBV_ILN_2012 
912 |a GBV_ILN_2018 
951 |a AR 
952 |d 30  |j 1984  |e 4  |b 01  |c 04  |h 537-43